Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2025)

Rocket Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 20.2% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 20.2%, while the annual FY2025 figure was $2.6 million, 20.2% down from the prior year.
  • Operating Leases for Q4 2025 was $2.6 million at Rocket Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $3.4 million in Q3 2024 and bottomed at $200000.0 in Q1 2023.
  • The 5-year median for Operating Leases is $1.3 million (2021), against an average of $1.8 million.
  • The largest YoY upside for Operating Leases was 407.26% in 2023 against a maximum downside of 72.18% in 2023.
  • A 5-year view of Operating Leases shows it stood at $905000.0 in 2021, then increased by 20.22% to $1.1 million in 2022, then skyrocketed by 173.25% to $3.0 million in 2023, then grew by 9.59% to $3.3 million in 2024, then fell by 20.2% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Operating Leases are $2.6 million (Q4 2025), $2.8 million (Q3 2025), and $2.9 million (Q2 2025).